Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer's Leadership Prepares For First Innovative Drug Launch In China Ahead Of U.S.

This article was originally published in PharmAsia News

Executive Summary

BEIJING - After obtaining regulatory approval for an innovative new anticoagulant in Beijing while a simultaneously filed application is still being reviewed by the U.S. FDA in Washington, DC, the leadership of Bayer Schering Pharma AG is now crafting a plan for the release of the drug in China ahead of the United States
Advertisement

Related Content

Bayer Taps Pfizer Emerging Markets Head To Lead Health Care Division
Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
China's State FDA Steps Up Transparency With First Annual Review Of Drug Approval Process, Outcome
China's State FDA Steps Up Transparency With First Annual Review Of Drug Approval Process, Outcome
Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population
Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population
Advertisement
UsernamePublicRestriction

Register

SC072726

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel